USPTO, FDA Sued Over Angiomax Patent Extension

Law360, New York (February 1, 2010, 4:40 PM EST) -- The Medicines Co. has hauled the U.S. Patent and Trademark Office, the Food and Drug Administration and the Department of Health and Human Services into court in an attempt to stretch the life of a patent covering its blood-thinner Angiomax, having narrowly missed the deadline for a patent extension.

MDCO filed a motion for summary judgment Friday, two days after lodging a complaint in the U.S. District Court for the Eastern District of Virginia, seeking to challenge the USPTO's decision to deny its request for a...
To view the full article, register now.